Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

MIXED(4)

DRUG(3)

Obinutuzumab

1 trial

phase_2

case-comprehensive-cancer-center

7 unique interventions2 categories

Analytics

Trial Phases

Phase 11

Phase 23

Trial Status

Completed1

Terminated1

Other1

Role Distribution

Principal Investigator3

PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT04517435Phase 1/2Terminated

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

PrincipalinvestigatorStart date: 2021-04-28

NCT02588651Phase 2Completed

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Adult T-cell Leukemia/LymphomaAngioimmunoblastic T-cell LymphomaEnteropathy Associated T-cell Lymphoma+3 more

PrincipalinvestigatorStart date: 2016-06-17

NCT03086395Phase 2Withdrawn

Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)

Post-transplant Lymphoproliferative DisorderPTLD

Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Adult T-Cell Leukemia/Lymphoma1 Angioimmunoblastic T-cell Lymphoma1 Lymphoma, Large B-Cell, Diffuse1 Enteropathy-Associated T-Cell Lymphoma1 Hepatosplenic T-cell Lymphoma1 NK T-Cell Lymphoma1 Post-Transplant Lymphoproliferative Disorder1 PTLD1

Affiliations

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Steven Horwitz, MD

Memorial Sloan Kettering Cancer Center

7 trials

Shared therapeutic areas:

Lymphoma, T-CellAdult T-Cell Leukemia/LymphomaAngioimmunoblastic T-cell Lymphoma+2 more

Similarity Score17%

Thomas E. Witzig, MD

Mayo Clinic

12 trials

Shared therapeutic areas:

Angioimmunoblastic T-cell LymphomaLymphoma, Large B-Cell, DiffuseEnteropathy-Associated T-Cell Lymphoma+1 more

Similarity Score13%

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

12 trials

Shared therapeutic areas:

Angioimmunoblastic T-cell LymphomaHepatosplenic T-cell LymphomaLymphoma, Large B-Cell, Diffuse+1 more

Similarity Score13%

David Maloney

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

11 trials

Shared therapeutic areas:

Angioimmunoblastic T-cell LymphomaHepatosplenic T-cell LymphomaPost-Transplant Lymphoproliferative Disorder

Similarity Score10%

Ryotaro Nakamura

City of Hope Medical Center

10 trials

Shared therapeutic areas:

Post-Transplant Lymphoproliferative DisorderAngioimmunoblastic T-cell Lymphoma

Similarity Score7%

James N Kochenderfer, M.D.

National Cancer Institute (NCI)

11 trials

Shared therapeutic areas:

Enteropathy-Associated T-Cell LymphomaLymphoma, Large B-Cell, Diffuse

Similarity Score7%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

17 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, Diffuse

Worked with same sponsors:

Genentech, Inc.

Similarity Score3%

Roberto Hernández Martín, MD

Hospital Virgen de la Concha

2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, Diffuse

Similarity Score3%

Elena Pérez Ceballos, MD

Hospital Morales Meseguer

2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, Diffuse

Similarity Score3%

Qifa Liu

Nanfang Hospital, Southern Medical University

33 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, Diffuse

Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT04517435Phase 1/2PrincipalInvestigator

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Terminated

NCT02588651Phase 2PrincipalInvestigator

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Adult T-cell Leukemia/LymphomaAngioimmunoblastic T-cell LymphomaEnteropathy Associated T-cell Lymphoma+3 more

Completed

NCT03086395Phase 2PrincipalInvestigator

Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)

Post-transplant Lymphoproliferative DisorderPTLD

Withdrawn

All 3 trials loaded